The Bio-effects of High Single-dose Radiation on Xenografts of Lewis Lung Carcinoma

WAN Xiao-li, LAN Jie, CHEN Yong-shun. et al

Abstract

To investigate the bio-effects of high single-dose radiation on xenografts of Lewis lung carcinoma. Methods Female 8-week-old C57 mice bearing 4-6 mm diameter Lewis lung carcinoma tumors in the hind legs were divided into 3 groups, control group (0 Gy), high single-dose group (12 Gy/one fraction/day) and routine radiation group (22 Gy/11 fraction/15 d). The mean biological effective dose (BED) of both radiation groups was 26.4 Gy. Changes in hypoxia, DNA damage and cell cycle of the tumor cells at 1, 3, 8, 15 and 21 d after first irradiation was assessed by immunofluorescence and flow-cytometry and the tumor growth curve was also made. Results Compared to the fractionated treatment, the tumor growth was delayed after single dose irradiation. The percent of hypoxic cells after single dose radiation was lower than fractioned irradiation at 3, 8, 15 d after first radiation. The foci of γ-H2AX showed that the single dose caused heavier DNA damages than fractioned irradiation at 1, 3 d after first radiation. The decline of G0/G1 percentage and increase of G2/M percentage of cells was found in both radiation schedules, but the G2/M percentage after single dose radiation was higher. Conclusion In the C57 mice bearing Lewis lung carcinoma, the high single-dose regimen inhibits the tumor growth more than fractioned irradiation. We hypothesized that conversion of high single-dose to BED using the LQ formalism under estimated the in vivo effect of hypofractionated radiation.

Key words: Non-small cell lung cancer, High single-dose, Xenograft of, Lewis lung carcinoma, Hypofractionated radiation therapy 


Full Text:

PDF


References


Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin,2010;60(5) :277-300.

Timmerman R, Paulus R, Galvin J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. J AM A, 2010; 303 (11): 1070-1076.

Lo SS, Fakiris AJ, Chang EL. et al. Stereotactic body radiation therapy; a novel treatment modality. Nat Rev Clin Oncol,2010;7(l):44-54.

Chi A, Liao Z, Nguyen NP, et al. Systemic review of the patterns of failure following stereotactic body radiation therapy in early-stage non-small-cell lung cancer: clinical implications. Radiother Oncol,2010;94( 1); 1-11.

Fakiris AJ, McGarry RC, Yiannoutsos CT. et al. Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase Ц study. Int J Radiat Oncol Biol Phys,2009;75(3) :677-682.

Chen Y, Guo W, Lu Y, et al. Dose-individualized stereotactic body radiotherapy for tl-3n0 non-small cell lung cancer: long¬term results and efficacy of adjuvant chemotherapy. Radiother Oncol, 2008; 88( 3); 351-358.

Zips D, Le K, Yaromina A, et al. Triple angiokinase inhibition, tumour hypoxia and radiation response of fadu human squamous cell carcinomas. Radiother Oncol, 2009; 92 (3):405-410.

Jankovic В, Aquino-Parsons С, Raleigh JA, etal. Comparison between pimonidazole binding. oxygen electrode measurements, and expression of endogenous hypoxia markers in cancer of the uterine cervix. Cytometry В Clin Cytom,2006; 70(2);45-55.

Zhou J, Liu W, Sun L. et al. Multiple defects of cell cycle checkpoints in U937-ASPI3K. an U937 cell mutant stably expressing anti-sense ATM gene cDNA. J Tongji Med Univ, 2000;20(4):273-276.

Deng R, Tang J, Ma JG, et al. Pkb/akt promotes dsb repair in cancer cells through upregulating mrel 1 expression following ionizing radiation. Oncogene,2011 ;30(8) :944-955.

Delaney G, Jacob S, Featherstone С, et al. The role of radiotherapy in cancer treatment: estimating optimal utilization from a review of evidence-based clinical guidelines. Cancer» 2005;104(6);1129-1137.

Delaney G, Barton M, Jacob S, et al. A model for decision making for the use of radiotherapy in lung cancer. Lancet Oncol,2003;4(2): 120-128.

Lagerwaard FJ, Haasbeek CJ, Smit EF, et al. Outcomes of risk-adapted fractionated stereotactic radiotherapy for stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys*2008; 70(3):685-692.

Brown JM, Koong AC. High-dose single-fraction radiotherapy; exploiting a new biology? Int J Radiat Oncol Biol Phys,2008;71(2):324-325.

Tatum JL, Kelloff GJ, Gillies RJ, et al. Hypoxia; importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int J Radiat Biol,2006;82( 10) :699-757.

Kallman RF. The phenomenon of reoxygenation and its implications for fractionated radiotherapy. Radiology, 1972; 105 (1): 135-142.

Carlson DJ, Keall PJ, Loo BW Jr, et al. Hypofractionation results in reduced tumor cell kill compared to conventional fractionation for tumors with regions of hypoxia. Int J Radiat Oncol Biol Phys,2011;79(4): 1188-1195.

Chen FH, Chiang CS, Wang CC, et al. Radiotherapy decreases vascular density and causes hypoxia with macrophage aggregation in tramp-cl prostate tumors, Clin Cancer Res,2009;15(5);1721-1729.

Wen QL, Meng MB. Yang B. et al. Endostar. a recombined humanized endostatin, enhances the radioresponse for human nasopharyngeal carcinoma and human lung adenocarcinoma xenografts in mice. Cancer Sci,2009;100(8);1510-1519.

Kocher M. Treuer H. Reoxygenation of hypoxic cells by tumor shrinkage during irradiation. A computer simulation. Strahlenther Onkol A 995; 171 (4) ;219-230.

Lan J, Wan XL. Deng L, et al. Ablative hypofractionated radiotherapy normalizes tumorvasculature in lewis lung carcinoma mice model. Radiat Res,2013; 179(4) ;458-464.

Rothkamm K, Horn S. Gamma-h2ax as protein biomarker for

radiation exposure. Ann 1st Super Sanita, 2009; 45 (3) ; 265- 271.

Kastan MB, Bartek J. Cell-cycle checkpoints and cancer. Nature»2004;432(7015):316-323.

Tobey RA. Different drugs arrest cells at a number of distinct stages in G2. Nature. 1975;254(5497) ;245-247.

Fowler JF, Stern BE. Dose-rate effects; some theoretical and practical considerations. Br J Radiol, 1960;33(390) ;389-395.

Radford IR, Hodgson GS, Matthews JP. Critical DNA target size model of ionizing radiation-induced mammalian cell death. Int J Radiat Biol,1988;54( 1):63-79.

Brenner DJ. The linear-quadratic model is an appropriate methodology for determining isoeffective doses at large doses per fraction. Semin Radiat Oncol,2008; 18(4):234-239.

Kirkpatrick JP. Meyer JJ, Marks LB. The linear-quadratic model is inappropriate to model high dose per fraction effects in radiosurgery. Semin Radiat Oncol,2008; 18(4):240-243.

Wang JZ, Huang Z, Lo SS, et al. A generalized linear- quadratic model for radiosurgery, stereotactic body radiation therapy, and high-dose rate brachytherapy. Sci Transl Med, 2010;2(39):39-48.

Park С, Papiez L, Zhang S. et al. Universal survival curve and single fraction equivalent dose; useful tools in understanding potency of ablative radiotherapy. Int J Radiat Oncol Biol Phys,2008;70(3);84 7-852.

Stuschke M, Pottgen C. Altered fractionation schemes in radiotherapy. Front Radiat Ther Oncol,2010;42; 150-156.

Garcia-Barros M, Paris F, Cordon-Cardo C, et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science,2003;300(5622): 1155-1159.

Szeifert GT, Atteberry DS, Kondziolka D, et al. Cerebral metastases pathology after radiosurgery; a multicenter study. Cancer,2006; 106(12) ;2672-2681.

Lee Y, Auh SL, Wang Y, et al. Therapeutic effects of ablative radiation on local tumor require CDS' T cells: changing strategies for cancer treatment. Blood,2009 ; 114(3);589-595.


Refbacks

  • There are currently no refbacks.